The degree of renal fibrosis was determined by
Trichrome staining kit (860–031; Ventana, Medical Systems, Inc. Roche Diagnostic USA). For the evaluation of renal injury score, ten tubulointerstitial fields were randomly selected and examined in terms of tubular dilatation, tubular atrophy, and interstitial fibrosis. Renal injury score was semi-quantitatively calculated based on the percentage of involved area with an assigned value: 0, none; 1, <10%; 2, 10% to 25%; 3, 25% to 75%; and 4, >75% as described elsewhere [24 (
link)].
Immunohistochemistry (IHC, Ventana Medical Systems, Inc) was performed as described in our previous study [22 (
link)]. For the specific method, we followed the manufacture’s instruction. Paraffin tissue sections (4μm) were analyzed for immunohistochemistry using monoclonal antibodies against α-SMA (
ab5694; Abcam, Cambridge, MA, USA), E-cadherin (
sc-7870; Santa Cruz Biotechnology, CA, USA), fibronectin (
ab6328; Abcam Cambridge, MA, USA) and Type IV collagen (
sc-9301; Santa Cruz Biotechnology CA, USA).
Ten individual high-power fields (magnification, 200 x) per kidney were analyzed, and representative images were presented.
Tsogbadrakh B., Ju K.D., Lee J., Han M., Koh J., Yu Y., Lee H., Yu K.S., Oh Y.K., Kim H.J., Ahn C, & Oh K.H. (2018). HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model. PLoS ONE, 13(8), e0201692.